Array joins Pfizer on anti-cancer combos, the latest in a string of binimetinib combinations
The plan is to test the potential benefits of combining molecularly targeted therapies with immunotherapies. The companies will start with combining Array’s MEK inhibitor binimetinib with Pfizer’s investigational PARP inhibitor talazoparib, and avelumab, a human anti-PD-L1 IgG1 monoclonal antibody.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.